SIGA Technologies focuses on antiviral treatments, with its lead product TPOXX (tecovirimat) approved for smallpox and other orthopoxviruses. The PALM 007 study of tecovirimat in monkeypox patients failed to meet its primary endpoint but showed safety. SIGA's reliance on US government contracts, especially for TPOXX, introduces substantial revenue concentration risk.
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Daniel Luckshire - Chief Financial Officer Conference Call Participants Soo Romanoff - Edison Group Operator Welcome to SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.
Siga Technologies Inc. (SIGA) reachead $9.72 at the closing of the latest trading day, reflecting a +0.83% change compared to its last close.
In the closing of the recent trading day, Siga Technologies Inc. (SIGA) stood at $9.06, denoting a +0.55% change from the preceding trading day.
Siga Technologies Inc. (SIGA) closed at $8.69 in the latest trading session, marking a +1.88% move from the prior day.
Siga Technologies Inc. (SIGA) reachead $7.88 at the closing of the latest trading day, reflecting a +1.81% change compared to its last close.